Practice Changing Events in Prostate Cancer- Charles Ryan

Practice Changing Events in Prostate Cancer, a Conversation with Alicia Morgans and Charles Ryan

Presentation from the 2017 annual LUGPA meeting in Chicago, IL

(Length of Discussion: 14 min)

Alicia Morgans, MD sits down with Charles Ryan, MD to discuss some of the practice changing events in prostate cancer and advanced prostate cancer in 2017.  Some of the highlights they cover are the LATITUDE and STAMPEDE trials as well as updates from CHAARTED chemohormonal study.  Dr. Ryan highlights there has been no new approvals but 2017 has been a year of learning to use the items they have better. They talk about the treatment outcomes of Abiraterone , ADT plus Abiraterone, and chemotherapy and the advantages that would come from a PAN 50 genomic test for the prostate cancer patient.  The finish up their conversation talking about the use of platinum agents in patients and in thinking about patient selection and they conclude talking about PSMA PET and how Dr. Ryan is thinking about integrating PSMA-PET  into his practice. 

View More Exclusive Coverage From LUGPA 2017

Additional Related Content: 

Watch: Charles Ryan's lecture on: Sequencing and Combining CRPC Therapies: What Does the Future Hold?

Watch: Discussion on CHAARTED, LATITUDE and STAMPEDE Trials

Watch: Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE

ASCO 2017: How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease

ESMO 2017: Benefits of Abiraterone Acetate Plus Prednisone When Added to Androgen Deprivation Therapy in LATITUDE on Patient Reported Outcomes